Joshua W Vincentz1, Beth A Firulli1, Kevin P Toolan1, Dan E Arking2, Nona Sotoodehnia3, Juyi Wan4,5, Peng-Sheng Chen4, Corrie de Gier-de Vries6, Vincent M Christoffels6, Michael Rubart-von der Lohe1, Anthony B Firulli1. 1. From the Herman B Wells Center for Pediatric Research, Departments of Pediatrics, Anatomy and Medical and Molecular Genetics, Indiana Medical School, Indianapolis (J.W.V., B.A.F., K.P.T., M.R.L., A.B.F.). 2. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD (D.E.A.). 3. Department of Epidemiology, Division of Cardiology, University of Washington, Seattle (N.S.). 4. Division of Cardiology, Department of Medicine, Krannert Institute of Cardiology, Indianapolis (J.W., P.-S.C.). 5. Department of Cardiothoracic Surgery, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, China (J.W.). 6. Department of Medical Biology, Academic Medical Center, University of Amsterdam, the Netherlands (C.d.G.V., V.M.C.).
Abstract
RATIONALE: The ventricular conduction system (VCS) rapidly propagates electrical impulses through the working myocardium of the ventricles to coordinate chamber contraction. GWAS (Genome-wide association studies) have associated nucleotide polymorphisms, most are located within regulatory intergenic or intronic sequences, with variation in VCS function. Two highly correlated polymorphisms (r2>0.99) associated with VCS functional variation (rs13165478 and rs13185595) occur 5' to the gene encoding the basic helix-loop-helix transcription factor HAND1 (heart- and neural crest derivatives-expressed protein 1). OBJECTIVE: Here, we test the hypothesis that these polymorphisms influence HAND1 transcription thereby influencing VCS development and function. METHODS AND RESULTS: We employed transgenic mouse models to identify an enhancer that is sufficient for left ventricle (LV) cis-regulatory activity. Two evolutionarily conserved GATA transcription factor cis-binding elements within this enhancer are bound by GATA4 and are necessary for cis-regulatory activity, as shown by in vitro DNA binding assays. CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9-mediated deletion of this enhancer dramatically reduces Hand1 expression solely within the LV but does not phenocopy previously published mouse models of cardiac Hand1 loss-of-function. Electrophysiological and morphological analyses reveals that mice homozygous for this deleted enhancer display a morphologically abnormal VCS and a conduction system phenotype consistent with right bundle branch block. Using 1000 Genomes Project data, we identify 3 additional single nucleotide polymorphisms (SNPs), located within the Hand1 LV enhancer, that compose a haplotype with rs13165478 and rs13185595. One of these SNPs, rs10054375, overlaps with a critical GATA cis-regulatory element within the Hand1 LV enhancer. This SNP, when tested in electrophoretic mobility shift assays, disrupts GATA4 DNA-binding. Modeling 2 of these SNPs in mice causes diminished Hand1 expression and mice present with abnormal VCS function. CONCLUSIONS: Together, these findings reveal that SNP rs10054375, which is located within a necessary and sufficient LV-specific Hand1 enhancer, exhibits reduces GATA DNA-binding in electrophoretic mobility shift assay, and this enhancer in total, is required for VCS development and function in mice and perhaps humans.
RATIONALE: The ventricular conduction system (VCS) rapidly propagates electrical impulses through the working myocardium of the ventricles to coordinate chamber contraction. GWAS (Genome-wide association studies) have associated nucleotide polymorphisms, most are located within regulatory intergenic or intronic sequences, with variation in VCS function. Two highly correlated polymorphisms (r2>0.99) associated with VCS functional variation (rs13165478 and rs13185595) occur 5' to the gene encoding the basic helix-loop-helix transcription factor HAND1 (heart- and neural crest derivatives-expressed protein 1). OBJECTIVE:Here, we test the hypothesis that these polymorphisms influence HAND1 transcription thereby influencing VCS development and function. METHODS AND RESULTS: We employed transgenicmouse models to identify an enhancer that is sufficient for left ventricle (LV) cis-regulatory activity. Two evolutionarily conserved GATA transcription factor cis-binding elements within this enhancer are bound by GATA4 and are necessary for cis-regulatory activity, as shown by in vitro DNA binding assays. CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9-mediated deletion of this enhancer dramatically reduces Hand1 expression solely within the LV but does not phenocopy previously published mouse models of cardiac Hand1 loss-of-function. Electrophysiological and morphological analyses reveals that micehomozygous for this deleted enhancer display a morphologically abnormal VCS and a conduction system phenotype consistent withright bundle branch block. Using 1000 Genomes Project data, we identify 3 additional single nucleotide polymorphisms (SNPs), located within the Hand1LV enhancer, that compose a haplotype withrs13165478 and rs13185595. One of these SNPs, rs10054375, overlaps with a critical GATA cis-regulatory element within the Hand1LV enhancer. This SNP, when tested in electrophoretic mobility shift assays, disrupts GATA4 DNA-binding. Modeling 2 of these SNPs in mice causes diminished Hand1 expression and mice present with abnormal VCS function. CONCLUSIONS: Together, these findings reveal that SNPrs10054375, which is located within a necessary and sufficient LV-specific Hand1 enhancer, exhibits reduces GATA DNA-binding in electrophoretic mobility shift assay, and this enhancer in total, is required for VCS development and function in mice and perhaps humans.
Authors: Alexandre T Soufan; Jan M Ruijter; Maurice J B van den Hoff; Piet A J de Boer; Jaco Hagoort; Antoon F M Moorman Journal: Physiol Genomics Date: 2003-05-13 Impact factor: 3.107
Authors: Benedetta A Pallante; Steven Giovannone; Liu Fang-Yu; Jie Zhang; Nian Liu; Guoxin Kang; Wen Dun; Penelope A Boyden; Glenn I Fishman Journal: Circ Arrhythm Electrophysiol Date: 2010-01-28
Authors: David G McFadden; Ana C Barbosa; James A Richardson; Michael D Schneider; Deepak Srivastava; Eric N Olson Journal: Development Date: 2004-12-02 Impact factor: 6.868
Authors: Ross A Breckenridge; Zia Zuberi; John Gomes; Robert Orford; Laurent Dupays; Leanne E Felkin; James E Clark; Anthony I Magee; Elisabeth Ehler; Emma J Birks; Paul J R Barton; Andrew Tinker; Timothy J Mohun Journal: J Mol Cell Cardiol Date: 2009-04-17 Impact factor: 5.000
Authors: Bijoy D Thattaliyath; Carolina B Livi; Mark E Steinhelper; Glenn M Toney; Anthony B Firulli Journal: Biochem Biophys Res Commun Date: 2002-10-04 Impact factor: 3.575
Authors: John C Chambers; Jing Zhao; Cesare M N Terracciano; Connie R Bezzina; Weihua Zhang; Riyaz Kaba; Manoraj Navaratnarajah; Amol Lotlikar; Joban S Sehmi; Manraj K Kooner; Guohong Deng; Urszula Siedlecka; Saurabh Parasramka; Ismail El-Hamamsy; Mark N Wass; Lukas R C Dekker; Jonas S S G de Jong; Michael J E Sternberg; William McKenna; Nicholas J Severs; Ranil de Silva; Arthur A M Wilde; Praveen Anand; Magdi Yacoub; James Scott; Paul Elliott; John N Wood; Jaspal S Kooner Journal: Nat Genet Date: 2010-01-10 Impact factor: 38.330
Authors: Joshua W Vincentz; Beth A Firulli; Kevin P Toolan; Marco Osterwalder; Len A Pennacchio; Anthony B Firulli Journal: Dev Biol Date: 2021-03-20 Impact factor: 3.148
Authors: Ammar J Alsheikh; Sabrina Wollenhaupt; Emily A King; Jonas Reeb; Sujana Ghosh; Lindsay R Stolzenburg; Saleh Tamim; Jozef Lazar; J Wade Davis; Howard J Jacob Journal: BMC Med Genomics Date: 2022-04-01 Impact factor: 3.063
Authors: Agatha Ribeiro da Silva; Elida A Neri; Lauro Thiago Turaça; Rafael Dariolli; Miriam H Fonseca-Alaniz; Artur Santos-Miranda; Danilo Roman-Campos; Gabriela Venturini; Jose E Krieger Journal: Sci Rep Date: 2020-09-30 Impact factor: 4.379